Vincent Ossipow
Founder chez OMEGA ALPHA SPAC
Fortune : 2 M $ au 31/03/2024
Profil
Vincent Ossipow is the founder and Chief Scientific Officer at Omega Alpha SPAC, which was founded in 2020.
He is currently a Director at BioInvent International AB since 2016, eTheRNA immunotherapies NV since 2016, FoRx Therapeutics AG since 2019, and NeoMed S.à.r.l.
since 2017.
He is also an Independent Non-Executive Director at SOPHiA GENETICS SA since 2014 and a Director at Aerium Therapeutics, Inc. He is a Partner at Omega Fund Management LLC since 2014 and a Member-Supervisory Board at Immunic AG.
Dr. Ossipow has held former positions as a Director at Lifespan, Inc., RainDance Technologies, Inc., Vital Therapies, Inc., and Kuros Biosciences Ltd.
from 2015 to 2016.
He was also a Director at Andrew Alliance SA and Luxe Trading SA. Dr. Ossipow served as an Independent Director at Immunic, Inc. from 2016 to 2023.
He was a Partner at Omega Funds and a Co-Manager at Pictet - Biotech.
He worked as an Investment Manager at Sectoral Asset Management, Inc. (Switzerland) from 2010 to 2013 and as a Partner & Financial Advisor at Covalence SA (Switzerland).
Dr. Ossipow started his career as a Research Analyst at Pictet Bank & Trust Ltd.
(Private Banking).
He holds graduate and doctorate degrees from the University of Geneva.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SOPHIA GENETICS SA
0,61% | 15/02/2024 | 395 502 ( 0,61% ) | 2 M $ | 31/03/2024 |
Postes actifs de Vincent Ossipow
| Sociétés | Poste | Début |
|---|---|---|
| SOPHIA GENETICS SA | Director/Board Member | 01/06/2014 |
| BIOINVENT INTERNATIONAL AB | Director/Board Member | 12/05/2016 |
| OMEGA ALPHA SPAC | Founder | 26/10/2020 |
| NeoMed S.à.r.l. | Private Equity Investor | 01/01/2017 |
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | Director/Board Member | - |
FoRx Therapeutics AG
 FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | 01/10/2019 |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Director/Board Member | - |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Director/Board Member | 01/03/2016 |
Omega Fund Management LLC
 Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Private Equity Investor | 01/03/2014 |
Anciens postes connus de Vincent Ossipow
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░ ░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░░ ░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ ░ ░░░░░░░ | - |
Formation de Vincent Ossipow
| University of Geneva | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BIOINVENT INTERNATIONAL AB | Health Technology |
| SOPHIA GENETICS SA | Technology Services |
| KUROS BIOSCIENCES AG | Health Technology |
| IMMUNIC, INC. | Health Technology |
| Entreprise privées | 17 |
|---|---|
Lifespan, Inc.
 Lifespan, Inc. Medical/Nursing ServicesHealth Services Lifespan, Inc. provides healthcare services. The company was founded on January 27, 1997 and is headquartered in Palm Desert, CA. | Health Services |
RainDance Technologies, Inc.
 RainDance Technologies, Inc. Medical SpecialtiesHealth Technology RainDance Technologies, Inc. engages in the development and commercialization of professional laboratory system. It develops and manufactures genomic tools for non-invasive liquid biopsy applications for the research, early detection, treatment of cancer, and inherited and infectious diseases. The company was founded by Andrew Griffiths, Darren R. Link, and Jerome Bibette in 2004 and is headquartered in Billerica, MA. | Health Technology |
| Omega Funds | Miscellaneous |
| Pictet - Biotech | Miscellaneous |
Vital Therapies, Inc.
 Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | Health Technology |
| NeoMed S.à.r.l. | Finance |
Sectoral Asset Management, Inc. (Switzerland)
 Sectoral Asset Management, Inc. (Switzerland) Investment ManagersFinance Sectoral Asset Management, Inc. (Switzerland) (Sectoral) is the Swiss subsidiary of Sectoral Asset Management, Inc. in Canada. Established in 2005, Sectoral is located in Geneva and has cooperated with Pictet Bank since the firm was founded. The firm is a healthcare equity specialist. They manage traditional portfolios as well as hedge funds, and sub-advise sector funds for third-party asset managers worldwide. They also manage discretionary portfolios for high-net worth individuals. The firm's clients include global pension plans, private banks and family offices. They also provide sub-advisory for institutional investors in Europe, North America and Asia. | Finance |
Covalence SA (Switzerland)
 Covalence SA (Switzerland) Investment ManagersFinance Covalence SA is an independent Swiss investment research firm which was co-founded by Antoine Mach and Marc Rochat in 2001. Headquartered in Carouge, the firm delivers data and research to corporates, academics and non-profits relying on its EthicalQuote reputation index. Their services includes ESG ratings, ESG news data, portfolio advisory, and impact stories, and support sustainable and responsible investment, ESG integration and impact investing strategies. Covalence is a socially responsible investor and signatory to the UN Principles for Responsible Investment (UNPRI). | Finance |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Finance |
Pictet Bank & Trust Ltd. (Private Banking)
 Pictet Bank & Trust Ltd. (Private Banking) Investment ManagersFinance Pictet Bank & Trust Ltd. (Private Banking) (Pictet Bank & Trust-PB) is the private banking arm of Pictet Bank & Trust Ltd., an offshore bank headquartered in Nassau, Bahamas. The firm was founded in 1978 and is a subsidiary of Banque Pictet & Cie SA, a Swiss private bank which specializes in asset and wealth management. Pictet Bank & Trust-PB provides wealth management and asset servicing for private clients. | Finance |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Health Technology |
Andrew Alliance SA
 Andrew Alliance SA Industrial MachineryProducer Manufacturing Andrew Alliance SA develops liquid handling solutions. Its product, Andrew, is a novel liquid handling robot designed for pipetting process. The firm's products include Andrew models, consumable dominos, protocol design, and enabling accessories. The company was founded by Piero Zucchelli, Giorgio Horak, and Antoine Jordan in March 2011 and is headquartered in Vernier, Switzerland. | Producer Manufacturing |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Health Technology |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Omega Alpha SPAC
 Omega Alpha SPAC Financial ConglomeratesFinance Omega Alpha SPAC is a blank check company. Its purposes effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Otello Stampacchia, Michelle Doig, Francesco Draetta and Vincent Ossipow on October 26, 2020 and is headquartered in Boston, MA. | Finance |
| Luxe Trading SA | |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | Commercial Services |
